Latest Blog Posts Tagged "Research News"
Uncovering the Promise of c-Abl as a Therapeutic Target: Testing Available Treatments and Supporting New Therapies
March 15, 2017
MJFF CEO Todd Sherer, PhD, discusses varied work happening around c-Abl inhibitors, an emerging therapeutic target that has shown early promise as a potential disease-modifying therapy.
February 14, 2017
A new study suggests that evaluating levels of a certain protein in the blood may help distinguish Parkinson's from certain atypical parkinsonisms.
February 14, 2017
This study is a major step for PD research as it is the first drug trial where one's genetic information determines eligibility and is testing a potential therapy to slow or stop disease progression.
February 10, 2017
MJFF funded early research of this novel drug candidate, mGluR4, helping remove financial and other barriers to advance its testing.
February 09, 2017
Pharmaceutical company Acorda reported positive results from a Phase III trial of an inhaled form of levodopa to treat "off" periods in Parkinson's.
January 17, 2017
Sarkis Mazmanian, PhD, of CalTech discusses what we know about the gut bacteria and Parkinson's connection in our "Getting to a Cure: The Science behind the Search" podcast series.
December 28, 2016
The Foundation is funding a clinical trial led by a team at Emory University and Hygieia Sciences, LLC, to define a Parkinson's-specific "breath fingerprint."
December 23, 2016
Some of our on-staff PhDs reflect on the work in 2016 that brought us closer to our goal of a world without Parkinson's disease.
December 20, 2016
Herantis Pharma was awarded a $6M grant to study the safety and efficacy of a potential therapy for Parkinson's disease (PD): cerebral dopamine neurotrophic factor (CDNF).
December 08, 2016
Voyager Therapeutics announced results from a trial, supported in early stages by MJFF, to help the brain convert levodopa to dopamine and better control motor symptoms.